The Pfizer-BioNTech <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine </a>is slightly less effective but still appears to offer protection against variant first detected in India, according to a study by France's Pasteur Institute.&nbsp;

"Despite slightly diminished efficacy, the Pfizer vaccine probably protects" against the strain first discovered in India, Olivier Schwartz, the institute's director and co-author of the study was quoted as saying by news agency AFP.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="http://wionews.com/videos/coronavirus-update-european-union-backs-pfizer-jab-for-12-15-year-old-388175/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

However, the study published on the BioRxiv website is still to be peer-reviewed.&nbsp;

Twenty-eight healthcare workers in the city of Orleans were part of the study, out of which 16 received two doses of the Pfizer-BioNTech vaccine, while 12 were given one dose of AstraZeneca-Oxford University vaccine.&nbsp;

There was a three-fold decrease in the number of antibodies of people who had taken the Pfizer-BioNTech vaccine against the B.1.617 variant, but still, there was protection.&nbsp;

Also read |&nbsp;<a href="http://wionews.com/world/european-regulator-approves-pfizer-biontech-vaccine-for-12-to15-year-olds-388097">European regulator approves Pfizer-BioNTech vaccine for 12 to15-year old</a>

"The situation was different with the AstraZeneca vaccine, which induced particularly low levels of antibodies neutralising" the variant first found in India, the study noted.&nbsp;

Schwartz said that people who got infected with COVID-19 within the last one year and people vaccinated with two jabs of Pfizer-BioNTech vaccine have enough antibodies to counter the B.1.617 variant.&nbsp;

The Pfizer-BioNTech coronavirus vaccine is slightly less effective but still appears to offer protection against variant first detected in India, according to a study by France's Pasteur Institute.

The Pfizer-BioNTech coronavirus vaccine is slightly less effective but still appears to offer protection against variant first detected in India, according to a study by France's Pasteur Institute. "Despite slightly diminished efficacy, the Pfizer vaccine probably protects" against the strain first discovered in India, Olivier Schwartz, the institute's director and co-author of the study was quoted as saying by news agency AFP. Watch | However, the study published on the BioRxiv website is still to be peer-reviewed. Twenty-eight healthcare workers in the city of Orleans were part of the study, out of which 16 received two doses of the Pfizer-BioNTech vaccine, while 12 were given one dose of AstraZeneca-Oxford University vaccine. There was a three-fold decrease in the number of antibodies of people who had taken the Pfizer-BioNTech vaccine against the B.1.617 variant, but still, there was protection. Also read | European regulator approves Pfizer-BioNTech vaccine for 12 to15-year old "The situation was different with the AstraZeneca vaccine, which induced particularly low levels of antibodies neutralising" the variant first found in India, the study noted. Schwartz said that people who got infected with COVID-19 within the last one year and people vaccinated with two jabs of Pfizer-BioNTech vaccine have enough antibodies to counter the B.1.617 variant.

Pfizer less effective, AstraZeneca even worse against variant first detected in India: Study

indian-coronavirus-variant

Indian Coronavirus Variant, News on Indian Coronavirus Variant, stories on Indian Coronavirus Variant, articles on Indian Coronavirus Variant, Indian Coronavirus Variant stories at Wion, Indian Coronavirus Variant news, Indian Coronavirus Variant latest news

indian coronavirus-variant

Pfizer less effective, AstraZeneca even worse against variant first detected in India: Study